MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$5,667,166
Unit: Dollar
Positive Cash Flow Breakdown
Unrealized gain from changes in ...
Proceeds from notes payable, net...
Accretion on convertible notes
Others
Negative Cash Flow Breakdown
Net loss
Realized gain and trading gains ...
Repayment of notes payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
-
-
1,632,581
-
General and administrative
-
-
10,279,981
-
Total operating expenses
-
-
11,912,562
-
Loss from operations
-
-
-11,912,562
-
Unrealized gain on digital assets
-
-
1,812,348
-
Realized gain on sale of digital assets
-
-
4,197,394
-
Trading gains, net
-
-
97
-
Foreign currency transaction loss
-
-
-521
-
Change in fv of warrant liability
-
-
0
-
Change in fv of derivative
-
-
-55,146
-
Interest income
-
-
107,595
-
Interest expense
-
-
283,011
-
Total other income (expense), net
-
-
5,911,425
-
Net loss
-20,173,130
-35,059,852
-1,155,292
-1,781,255
Stock based compensation - option grants
105,210
114,166
0
0
Stock based compensation - stock options and warrants
-
-
1,331,079
42,674
Change in fair value of warrant liability
-
-
0
-12,859
Advisory shares committed for issuance
0
8,113,318
-
-
Depreciation & amortization expense
-
20,044
3,985
1,489
Depreciation and amortization expense
40,324
-
-
-
Accrued interest expense - related parties
-
-
-
6,301
Change in fair value of derivative liability
215,993
48,279
55,146
-
Interest expense
-
8,387
243,177
1
Non-cash interest
1,212,398
-
-
-
Accretion on convertible notes
1,859,744
851,018
-
-
Unrealized gain from changes in fair value of digital assets
-13,196,057
-22,061,472
6,009,838
-
Realized gain and trading gains on digital assets
2,004,495
-
-
-
Digital assets received as yield income
282,732
-
-
-
Non-cash digital asset operating expenses
-
8,726
2,429,487
-
Proceeds from sales of digital assets, net of purchases
177,901
-
-
-
Prepaid expenses and other current assets
-296,013
273,390
193,457
431,011
Accounts payable and accrued expenses
168,453
2,134,541
-384,643
448,494
Operating lease liability
-9,758
2,122
-
-
Net cash used in operating activities
-5,667,166
-2,067,727
-3,818,202
-1,726,166
Cash from short term investments
-
-
2,000,000
-
Restricted cash
-
-
8,000,000
-
Redemption of short term investments
-1,500,000
-500,000
-
-
Purchases of property, plant and equipment
0
9,394
21,424
22,540
Cash paid to acquire operating lease
-
-
18,363
-
Cash acquired in accordance with merger
-
-
-15,345
-
Net cash provided by (used in) investing activities
1,500,000
490,606
-10,024,442
-22,540
Cash proceeds from issuance of common stock in ipo
-
-
-323,319
0
Proceeds from notes payable, net of original issue discount
5,970,000
-
100
0
Proceeds from notes payable
-
995,000
10,000,000
-
Payment of debt issuance costs
510,000
75,000
946,000
-
Cash advances from related parties
-
-
11,900
0
Repayment of notes payable
1,000,000
-
-
-
Cash advances paid to related parties
-
-
250,000
0
Proceeds from subscription receivable on subsidiary shares
1,002
-
-
-
Net cash provided by financing activities
3,466,002
920,000
8,492,681
0
Net change in cash and cash equivalents
-701,163
-657,121
-5,349,962
-1,748,706
Cash, cash equivalents, and restricted cash, beginning of period
6,986,617
6,986,617
6,986,617
3,455
Cash, cash equivalents and restricted cash, end of period
8,278,371
-
-
-
Cash paid for interest
160,000
-
-
-
Debt issuance costs accrued in connection with notes payable
865,000
-
-
-
Restricted cash
-
8,000,000
8,000,000
-
Cash and cash equivalents
278,371
-
-
-
Total cash, cash equivalents, and restricted cash
8,278,371
8,979,534
-
6,986,617
Total cash, cash equivalents, and restricted cash
-
8,979,534
-
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from notes
payable, net of original...
$5,970,000
(2288.00%↑ Y/Y)
Redemption of short term
investments
-$1,500,000
Proceeds from
subscription receivable on...
$1,002
Net cash provided by
financing activities
$3,466,002
(-71.42%↓ Y/Y)
Net cash provided by
(used in) investing...
$1,500,000
(11319.99%↑ Y/Y)
Canceled cashflow
$2,505,000
Net change in cash
and cash...
-$701,163
(-108.03%↓ Y/Y)
Canceled cashflow
$4,966,002
Unrealized gain from
changes in fair value of...
-$13,196,057
Accretion on convertible
notes
$1,859,744
Non-cash interest
$1,212,398
Prepaid expenses and
other current assets
-$296,013
(-116.55%↓ Y/Y)
Proceeds from sales of
digital assets, net of...
$177,901
Accounts payable and
accrued expenses
$168,453
(135.69%↑ Y/Y)
Stock based
compensation - option grants
$105,210
(-93.81%↓ Y/Y)
Depreciation and
amortization expense
$40,324
Repayment of notes payable
$1,000,000
something is missing
-$995,000
Payment of debt issuance
costs
$510,000
Net cash used in
operating activities
-$5,667,166
(-67.60%↓ Y/Y)
Canceled cashflow
$17,056,100
Net loss
-$20,173,130
(-558.27%↓ Y/Y)
Realized gain and trading
gains on digital...
$2,004,495
Digital assets received
as yield income
$282,732
Change in fair value of
derivative liability
$215,993
Operating lease liability
-$9,758
Buy us a coffee
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)